Agios Pharmaceuticals, Inc.
DE ˙ DB ˙ US00847X1046
24,20 € ↑0,80 (3,42%)
2026-06-05
DEL PRIS
SecurityDE:8AP / Agios Pharmaceuticals, Inc.
InstitutionCaligan Partners LP
ManagerDavid Johnson
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Caligan Partners LP ownership in 8AP / Agios Pharmaceuticals, Inc.

On February 17, 2026 - Caligan Partners LP filed a 13F-HR form disclosing ownership of 0 shares of Agios Pharmaceuticals, Inc. (DE:8AP) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 1,131,205 shares of Agios Pharmaceuticals, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Caligan Partners LP has a history of taking positions in derivatives of the underlying security (8AP) in the form of stock options. The firm currently holds call options representing 90,000 of underlying shares valued at $3,044,700 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:8AP / Agios Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 0 -1,131,205 -100.00 0 -100.00
2025-11-14 2025-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 1,131,205 59,947 5.60 45,407 27.44 5.9471
2025-08-14 2025-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 1,071,258 369,978 52.76 35,630 73.41 6.8497
2025-05-15 2025-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 701,280 75,000 11.98 20,548 -0.16 4.2876
2025-02-14 2024-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 626,280 46,563 8.03 20,580 -20.10 5.2116
2024-11-14 2024-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 579,717 65,006 12.63 25,757 16.05 8.1645
2024-08-14 2024-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 514,711 30,000 6.19 22,194 56.60 5.1856
2024-05-13 2024-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 484,711 42,878 9.70 14,173 44.04 3.7463
2024-02-14 2023-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 441,833 437,000 9,042.00 9,840 8,168.07 3.3183
2023-11-14 2023-09-30 13F AGIOS PHARMACEUTICALS COM 00847X104 4,833 0 0.00 120 -12.50 0.0549
2023-08-14 2023-06-30 13F AGIOS PHARMACEUTICALS COM 00847X104 4,833 500 11.54 137 37.37 0.0770
2023-05-15 2023-03-31 13F AGIOS PHARMACEUTICALS COM 00847X104 4,333 0 0.00 100 -18.18 0.0694
2023-05-15 2022-12-31 13F/A-1 AGIOS PHARMACEUTICALS COM 00847X104 4,333 4,333 122 0.1013
2023-02-15 2022-12-31 13F AGIOS PHARMACEUTICALS COM 00847X104 4,333 4,333 122 0.0965
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F AGIOS PHARMACEUTICALS COM Call 90,000 0.00 3,045 24.30 n/a n/a n/a
2026-02-17 2025-12-31 13F AGIOS PHARMACEUTICALS COM Call 90,000 2,450 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-17 2025-12-31 13F AGIOS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F AGIOS PHARMACEUTICALS COM Put 975,000 39,136 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.